Published in J Biol Chem on December 14, 2009
Neonatal Fc receptor and IgG-based therapeutics. MAbs (2011) 1.56
Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol (2010) 1.50
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem (2010) 1.27
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. MAbs (2016) 1.23
The proximal tubule and albuminuria: really! J Am Soc Nephrol (2014) 1.19
Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun (2012) 1.19
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun (2011) 1.11
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs (2015) 1.10
Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs (2015) 1.02
Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs (2012) 0.94
Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs (2014) 0.93
Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods (2013) 0.92
Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem (2012) 0.90
Pulmonary microvascular albumin leak is associated with endothelial cell death in murine sepsis-induced lung injury in vivo. PLoS One (2014) 0.89
CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med (2015) 0.89
Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J Biol Chem (2013) 0.88
Clinical chemistry of human FcRn transgenic mice. Mamm Genome (2011) 0.88
Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem (2014) 0.87
Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions. Front Immunol (2015) 0.86
Polymeric human Fc-fusion proteins with modified effector functions. Sci Rep (2011) 0.86
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev (2015) 0.84
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. J Control Release (2015) 0.81
Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies. J Biol Chem (2014) 0.81
Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn). J Biol Chem (2014) 0.80
Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. AAPS J (2012) 0.80
Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. MAbs (2015) 0.80
Using 2-photon microscopy to understand albuminuria. Trans Am Clin Climatol Assoc (2014) 0.78
Robust expression of the human neonatal Fc receptor in a truncated soluble form and as a full-length membrane-bound protein in fusion with eGFP. PLoS One (2013) 0.78
Selection of nanobodies that target human neonatal Fc receptor. Sci Rep (2013) 0.78
Challenges and advances in the assessment of the disposition of antibody-drug conjugates. Biopharm Drug Dispos (2015) 0.78
Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J Control Release (2016) 0.77
Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia. Sci Rep (2015) 0.77
Binding structures and energies of the human neonatal Fc receptor with human Fc and its mutants by molecular modeling and dynamics simulations. Mol Biosyst (2013) 0.77
Genetically engineered humanized mouse models for preclinical antibody studies. BioDrugs (2014) 0.77
A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery. J Pharm Sci (2012) 0.76
Novel ubiquitin-derived high affinity binding proteins with tumor targeting properties. J Biol Chem (2014) 0.76
High-dose IgG therapy mitigates bile duct-targeted inflammation and obstruction in a mouse model of biliary atresia. Pediatr Res (2014) 0.76
Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proc Natl Acad Sci U S A (2017) 0.75
Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. MAbs (2015) 0.75
Mechanism of increased clearance of glycated albumin by proximal tubule cells. Am J Physiol Renal Physiol (2016) 0.75
Antibody blood-brain barrier efflux is modulated by glycan modification. Biochim Biophys Acta (2017) 0.75
Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes. PLoS One (2017) 0.75
FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94
Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol (2005) 5.80
An Fc receptor structurally related to MHC class I antigens. Nature (1989) 4.32
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol (2003) 3.09
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol (2001) 2.87
Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature (1994) 2.85
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol (2005) 2.82
Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell (2001) 2.67
The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med (2003) 2.63
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol (2006) 2.32
Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem (2003) 2.03
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol (2001) 1.93
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res (2005) 1.88
An engineered human IgG1 antibody with longer serum half-life. J Immunol (2006) 1.88
Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry (2000) 1.87
Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A (2008) 1.82
Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem (2002) 1.76
Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A (2004) 1.69
Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol (1999) 1.61
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res (2007) 1.59
Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry (2006) 1.57
Perspective-- FcRn transports albumin: relevance to immunology and medicine. Trends Immunol (2006) 1.55
Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol (1997) 1.45
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol (2005) 1.42
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res (2007) 1.40
Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A (2006) 1.39
Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol (1997) 1.39
Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem (2007) 1.36
Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol (1991) 1.36
Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Invest (1990) 1.35
The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol (2006) 1.32
Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry (1999) 1.31
Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos (2006) 1.28
Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol (2007) 1.27
Conformational stability of pGEX-expressed Schistosoma japonicum glutathione S-transferase: a detoxification enzyme and fusion-protein affinity tag. Protein Sci (1997) 1.27
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A (2006) 1.26
Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J Mol Biol (2004) 1.21
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel (2008) 1.17
Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol (2003) 1.15
Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res (2002) 1.14
Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol (2003) 1.14
Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods (1997) 1.12
Glutathione S-transferase can be used as a C-terminal, enzymatically active dimerization module for a recombinant protease inhibitor, and functionally secreted into the periplasm of Escherichia coli. Protein Sci (1997) 1.10
High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. Biochemistry (1997) 1.10
A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel (2007) 1.05
Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J Immunol Methods (2005) 1.03
Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp Hematol (2004) 0.99
Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem (2001) 0.99
Fc-based cytokines : prospects for engineering superior therapeutics. BioDrugs (2008) 0.98
Over-expression of the bovine FcRn in the mammary gland results in increased IgG levels in both milk and serum of transgenic mice. Immunology (2007) 0.97
Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol (2008) 0.94
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther (2006) 0.93
Turnover of serum proteins in rats with analbuminemia. Biochem Biophys Res Commun (1979) 0.91
The heavy chain of neonatal Fc receptor for IgG is sequestered in endoplasmic reticulum by forming oligomers in the absence of beta2-microglobulin association. Biochem J (2002) 0.89
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol (2006) 0.87
Fc receptor-mediated transport of immunoglobulin across the intestinal epithelium of the neonatal rodent. Immunol Today (1984) 0.78
Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov (2003) 2.13
In vitro assessment of recombinant, mutant immunoglobulin G anti-D devoid of hemolytic activity for treatment of ongoing hemolytic disease of the fetus and newborn. Transfusion (2007) 1.50
Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A (2011) 1.44
The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol (2006) 1.32
Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem (2010) 1.27
The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet (2009) 1.22
Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun (2012) 1.19
Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci U S A (2009) 1.17
Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood (2003) 1.14
Identification of residues in the Cmu4 domain of polymeric IgM essential for interaction with Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). J Immunol (2008) 1.12
Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun (2011) 1.11
Posttranslational modification of gluten shapes TCR usage in celiac disease. J Immunol (2011) 1.11
Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis. Infect Immun (2005) 1.06
Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells. J Immunol Methods (2005) 1.03
A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood (2013) 1.03
A complement fixing polysaccharide from Biophytum petersianum Klotzsch, a medicinal plant from Mali, West Africa. Biomacromolecules (2006) 1.02
Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm types, multilocus sequence types, and superantigen profiles. J Clin Microbiol (2009) 0.99
Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity. ACS Chem Biol (2012) 0.97
FcRn binding properties of an abnormal truncated analbuminemic albumin variant. Clin Biochem (2009) 0.97
Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. FEBS J (2008) 0.94
Bioactive pectic polysaccharides from Glinus oppositifolius (L.) Aug. DC., a Malian medicinal plant, isolation and partial characterization. J Ethnopharmacol (2005) 0.94
A practical approach to T-cell receptor cloning and expression. PLoS One (2011) 0.93
Structural requirements for the interaction of human IgM and IgA with the human Fcalpha/mu receptor. Eur J Immunol (2009) 0.93
Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther (2004) 0.93
A strategy for bacterial production of a soluble functional human neonatal Fc receptor. J Immunol Methods (2007) 0.92
The malian medicinal plant Trichilia emetica; studies on polysaccharides with complement fixing ability. J Ethnopharmacol (2003) 0.92
Polysaccharides with complement fixing and macrophage stimulation activity from Opilia celtidifolia, isolation and partial characterisation. J Ethnopharmacol (2007) 0.92
Reliable titration of filamentous bacteriophages independent of pIII fusion moiety and genome size by using trypsin to restore wild-type pIII phenotype. Biotechniques (2008) 0.92
DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther (2006) 0.91
Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem (2012) 0.90
Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J Biol Chem (2013) 0.88
Bioactive polysaccharides from the stems of the Thai medicinal plant Acanthus ebracteatus: their chemical and physical features. Carbohydr Res (2004) 0.88
Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation. J Immunol (2013) 0.87
Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation. Biophys J (2007) 0.87
The carboxyl-terminal domains of IgA and IgM direct isotype-specific polymerization and interaction with the polymeric immunoglobulin receptor. J Biol Chem (2002) 0.87
Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem (2014) 0.87
Structural and immunological studies of a pectin and a pectic arabinogalactan from Vernonia kotschyana Sch. Bip. ex Walp. (Asteraceae). Carbohydr Res (2005) 0.87
Expanding the versatility of phage display II: improved affinity selection of folded domains on protein VII and IX of the filamentous phage. PLoS One (2011) 0.86
Polymeric human Fc-fusion proteins with modified effector functions. Sci Rep (2011) 0.86
A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells. Eur J Immunol (2006) 0.85
An immunomodulating pectic polymer from Glinus oppositifolius. Phytochemistry (2007) 0.85
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel (2012) 0.85
Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol (2012) 0.84
Structures and structure-activity relationships of three mitogenic and complement fixing pectic arabinogalactans from the malian antiulcer plants Cochlospermum tinctorium A. Rich and Vernonia kotschyana Sch. Bip. ex Walp. Biomacromolecules (2006) 0.84
A receptor-mediated mechanism to support clinical observation of altered albumin variants. Clin Chem (2007) 0.83
Structural features and complement-fixing activity of pectin from three Brassica oleracea varieties: white cabbage, kale, and red kale. Biomacromolecules (2007) 0.82
Crystallohydrodynamics of protein assemblies: Combining sedimentation, viscometry, and x-ray scattering. Biophys J (2006) 0.82
Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J Immunol (2002) 0.82
Next generation phage display by use of pVII and pIX as display scaffolds. Methods (2012) 0.81
A comparison of bioactive aqueous extracts and polysaccharide fractions from roots of wild and cultivated Cochlospermum tinctorium A. Rich. Phytochemistry (2013) 0.81
Differential segmental flexibility and reach dictate the antigen binding mode of chimeric IgD and IgM: implications for the function of the B cell receptor. J Immunol (2004) 0.81
The cytoplasmic tail of invariant chain modulates antigen processing and presentation. Eur J Immunol (2003) 0.81
Identification of a polymeric Ig receptor binding phage-displayed peptide that exploits epithelial transcytosis without dimeric IgA competition. J Biol Chem (2006) 0.81
Chaperone-assisted thermostability engineering of a soluble T cell receptor using phage display. Sci Rep (2013) 0.81
Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region. Mol Immunol (2002) 0.80
Selection of nanobodies that target human neonatal Fc receptor. Sci Rep (2013) 0.78
Structure-immunomodulating activity relationships of a pectic arabinogalactan from Vernonia kotschyana Sch. Bip. ex Walp. Carbohydr Res (2005) 0.78
MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation. Int Immunol (2003) 0.78
Direct isolation of recombinant human antibodies against group B Neisseria meningitidis from scFv expression libraries. J Immunol Methods (2003) 0.78
Pectic polysaccharides from Biophytum petersianum Klotzsch, and their activation of macrophages and dendritic cells. Glycobiology (2008) 0.78
Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA. BMC Biotechnol (2010) 0.78
Bioactive arabinogalactans from the leaves of Opilia celtidifolia Endl. ex Walp. (Opiliaceae). Glycobiology (2010) 0.77
DeltaPhage--a novel helper phage for high-valence pIX phagemid display. Nucleic Acids Res (2012) 0.77
Processing of an antigenic sequence from IgG constant domains for presentation by MHC class II. J Immunol (2008) 0.77
Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. Blood (2013) 0.77
CD40/APC-specific antibodies with three T-cell epitopes loaded in the constant domains induce CD4+ T-cell responses. Protein Eng Des Sel (2012) 0.77
Expanding the versatility of phage display I: efficient display of peptide-tags on protein VII of the filamentous phage. PLoS One (2011) 0.77
Anti-ulcer polysaccharides from Cola cordifolia bark and leaves. J Ethnopharmacol (2012) 0.77
Immunomodulatory activity of dietary fiber: arabinoxylan and mixed-linked beta-glucan isolated from barley show modest activities in vitro. Int J Mol Sci (2011) 0.77
Induction of central T cell tolerance: recombinant antibodies deliver peptides for deletion of antigen-specific (CD4+)8+ thymocytes. Eur J Immunol (2005) 0.76
Recombinant antibodies for delivery of antigen: a single loop between beta-strands in the constant region can accommodate long, complex and tandem T cell epitopes. Int Immunol (2008) 0.76
Immunological and structural properties of a pectic polymer from Glinus oppositifolius. Glycobiology (2007) 0.76
Identification of a high affinity FcgammaRIIA-binding peptide that distinguishes FcgammaRIIA from FcgammaRIIB and exploits FcgammaRIIA-mediated phagocytosis and degradation. J Biol Chem (2008) 0.76
Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation. Xenotransplantation (2006) 0.76
Stabilizing mutations increase secretion of functional soluble TCR-Ig fusion proteins. BMC Biotechnol (2010) 0.76
The arabidopsis histone methyltransferase SUVR4 binds ubiquitin via a domain with a four-helix bundle structure. Biochemistry (2014) 0.76
Balanced expression of single subunits in a multisubunit protein, achieved by cell fusion of individual transfectants. Eur J Biochem (2002) 0.75
Hot-water extracts from the inner bark of Norway spruce with immunomodulating activities. Carbohydr Polym (2013) 0.75
Corrigendum: Antibody-antigen kinetics constrain intracellular humoral immunity. Sci Rep (2017) 0.75
In vitro functional test of two subclasses of an anti-RhD antibody produced by transient expression in COS cells. APMIS (2006) 0.75
Pectin isolated from white cabbage--structure and complement-fixing activity. Mol Nutr Food Res (2006) 0.75
Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D. Transfusion (2007) 0.75
Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes. J Leukoc Biol (2004) 0.75